Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

NCT07671911 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

306

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: NAL ER
DRUG: Placebo

Sponsor

Trevi Therapeutics